| Literature DB >> 28694828 |
Daniel W Gunda1, Igembe Nkandala1, Godfrey A Kavishe1, Semvua B Kilonzo1, Rodrick Kabangila1, Bonaventura C Mpondo2.
Abstract
INTRODUCTION: Smear positive TB carries high morbidity and mortality. The TB treatment aims at sputum conversion by two months of antituberculous. Patients who delay sputum conversion remain potentially infectious, with risk of treatment failure, drug resistance, and mortality. Little is known about the magnitude of this problem in our setting. This study was designed to determine the prevalence and risk factors of delayed sputum conversion in northwestern rural part of Tanzania.Entities:
Year: 2017 PMID: 28694828 PMCID: PMC5485336 DOI: 10.1155/2017/5352906
Source DB: PubMed Journal: J Trop Med ISSN: 1687-9686
Demographic and laboratory characteristics of 156 study participants.
| Variables | Frequency | Median (IQR) or percentage |
|---|---|---|
| Sex | ||
| Male | 97 | 62.2 |
| Female | 59 | 37.8 |
| Age | 156 | 39 [30–51] |
| Age group | ||
| ≥50 years | 45 | 28.8 |
| <50 years | 111 | 71.2 |
| Resides in SGM | ||
| Yes | 18 | 11.5 |
| No | 138 | 88.5 |
| HIV status | ||
| Positive | 55 | 35.3 |
| Negative | 101 | 64.7 |
| Median AFB+ | 156 | 2 [2-3] |
| Smear conversion | ||
| Median (months) | 156 | 2 [2-2] |
| >2 months | 13 | 8.3 |
| ≤2 months | 143 | 91.7 |
AFB: Acid Fast Bacilli; HIV: human immunodeficiency virus; IQR: interquartile range.
Figure 1Distribution of smear positivity at treatment initiation.
Figure 2Distribution of sputum smear conversion by time on anti-TB.
Factors associated with delayed sputum smear conversion among 156 study participants treated with potent anti-TB medications.
| Variables | Delayed smear conversion | OR (95% CI) |
| |
|---|---|---|---|---|
| No ( | Yes ( | |||
| Sex | ||||
| Male | 85 (59.4) | 12 (92.3) | ||
| Female | 58 (40.6) | 01 (7.7) | 8.2 (1.0–64.7) | 0.046 |
| Age | 38 [29–50] | 53 [40–59] | 1.1 [1.0–1.1] | 0.013 |
| Age group | ||||
| ≥50 years | 36 (25.2) | 09 (69.2) | ||
| <50 years | 107 (74.8) | 04 (30.8) | 6.7 (1.9–23.0) | 0.003 |
| Resides in SGM | ||||
| Yes | 17 (11.9) | 01 (7.7) | ||
| No | 126 (88.1) | 12 (92.3) | 0.6 (0.1–5.0) | 0.653 |
| HIV status | ||||
| Positive | 50 (34.9) | 05 (38.5) | ||
| Negative | 93 (65.1) | 08 (61.5) | 1.2 (0.4–3.7) | 0.801 |
| Median AFB+ | 3 [3-3] | 2 [2-3] | 6.5 (1.5–27.3) | 0.011 |
| Smear bacilli density | ||||
| AFB 1+ | 26 (18.2) | 00 (00.0) | — | — |
| AFB 2+ | 59 (41.3) | 02 (15.4) | 0.3 (0.1–1.2) | 0.086 |
| AFB 3+ | 58 (40.5) | 11 (84.6) | 8.1 (1.7–37.7) | 0.008 |
AFB: Acid Fast Bacilli; HIV: human immunodeficiency virus; CI: confidence interval; SGM: Sengerema.